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ABSTRACT  
 
An Examination of the Inhibitory Effects of Antibiotic Combinations on Ribosome 
Biosynthesis in Staphylococcus aureus 
 
by 
Justin Michael Beach 
 
Bacteremia initiated by Staphylococcus aureus infections can be a serious 
medical problem.  Although a number of different antibiotics are used to combat 
staphylococcal infections, resistance has continued to develop. Combination 
therapy for certain infections has been used to reduce the emergence of 
resistance when a single agent has become ineffective.  We hypothesize that the 
use of rifampicin and ciprofloxacin in combination with azithromycin, known for its 
inhibitory effects on the bacterial ribosome, can create potential synergistic 
effects resulting from indirect effects on ribosomal subunit synthesis.    
   
To determine this we measured the effects of single and multiple antibiotics on 
cell growth rates, cell viability, and synthesis rates for DNA, RNA, and protein.  
We then measured synthesis rates of ribosomal subunits and the amounts of 
gyrase and RNAP.  Effects of the antibiotic combinations on 70S ribosomes was 
assayed and the amounts of RNA and degradation was measured. We lastly 
	   3	  
studied the effects of these antibiotic combinations on mutation frequency in 
Staphylococcus aureus. 
  
Our data have shown support not only for the use of antibiotic combination 
therapy but have provided strong evidence of an increase in the inhibition of 
bacterial ribosome assembly in Staphylococcus aureus.  The reduction of 50S 
ribosomal subunit synthesis and 23S ribosomal RNA in cells grown in the 
presence of azithromycin, already known for it’s inhibitory effects on the 50S 
subunit synthesis, in combination with rifampicin or in combination with rifampicin 
and ciprofloxacin was observed. This also resulted in a reduction or elimination in 
the frequency of resistant cells when grown in the presence of these 
combinations.   
   
These studies have shed light on the mechanism of action involved and 
synergistic effects occurring in combination antibiotic treatments and how 
ribosomal subunit assembly is affected. The insights gained through this 
research provide necessary information needed for the design of more potent 
antibiotic combinations.   This will create a better understanding and new 
methods for eliminating the spread of harmful pathogens such as 
Staphylococcus aureus. 
 
 
 
 
	   4	  
DEDICATION 
 
This manuscript is dedicated to: 
 
Garrett:  You’re too young to understand this now, but I hope that one day you’ll 
pick this up and remember that this and everything else I do has always been, 
and will always be, for you.  I love you, son.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   5	  
ACKNOWLEDGEMENTS  
 
Thank you to Dr. Champney for all of your guidance and support.  Not 
many graduate advisors or people in general would have been as patient and 
understanding during these last few years.  
 
I would like to thank my committee members: Dr. Alok Agrawal, Dr. 
Donald Hoover, Dr. Antonio Rusinol, and Dr. Doug Thewke for their time and 
advice.  
 
Thank you to Beverly Sherwood and Angela Thompson for always going 
above and beyond what is necessary and for the countless times you’ve been 
there to listen and help me for anything I have needed.  
 
Thank you to my family, friends, fellow lab mates and graduate students 
for your advice, support, and absolute kindness during all of this.  I certainly 
could not have made it this far without some of you.  
 
A special thank you to Ward Rodgers for his contributions not only to this 
work, but to my now extensive recognition of 80s rock and endless football 
knowledge.  
 
Brigitte Browe, this * is for you.  Thank you for everything.  
	   6	  
 
This work was supported by the National Institutes of Health AREA grant 
awarded to Dr. W. Scott Champney and the ETSU Graduate School Research 
grant awarded to Justin M. Beach. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   7	  
TABLE OF CONTENTS 
 Page 
 
ABSTRACT  ............................................................................................................  2 
LIST OF TABLES  ...................................................................................................  10 
LIST OF FIGURES  .................................................................................................  11 
LIST OF ABBREVIATIONS .....................................................................................  16 
Chapter 
1. INTRODUCTION .................................................................................................  18 
Antibiotic Overview .......................................................................................  18 
Antibiotic Targets ..........................................................................................  21 
 Azithromycin ...........................................................................................  23 
 Rifampicin ...............................................................................................  25 
 Ciprofloxacin ...........................................................................................  26 
Combination Therapy  ..................................................................................  27 
Model  ...........................................................................................................  30 
Research Hypothesis ...................................................................................  31 
Specific Research Aims ...............................................................................  32 
2. MATERIALS AND METHODS  ...........................................................................  33 
Analysis of Cellular Growth and Viability ......................................................  33 
DNA Synthesis Assays .................................................................................  33 
RNA Synthesis Assays .................................................................................  34 
Protein Synthesis Assays .............................................................................  34 
	   8	  
Uridine Pulse and Chase Labeling ...............................................................  34 
70S Ribosome Synthesis Assay ..................................................................  35 
Preparation of Cellular Lysates ....................................................................  35 
Western Blot Analysis ..................................................................................  36 
Agilent Bioanalysis of Total Cellular RNA ....................................................  37 
Northern Blot Hybridization ..........................................................................  38 
Mutation Frequency Assays .........................................................................  39 
Statistical Analysis ........................................................................................  39 
 3. RESULTS  .......................................................................................................  40 
IC50 Determination  .......................................................................................  40 
Effects of Antibiotic Combinations on Cellular Growth Rates  ......................  43 
Effects of Antibiotic Combinations on Cellular Viability  ...............................  44 
Effects of Antibiotic Combinations on DNA Synthesis Rates  ......................  46 
Effects of Antibiotic Combinations on RNA Synthesis Rates .......................  49 
Effects of Antibiotic Combinations on Protein Synthesis Rates  ..................  52 
Effects of Antibiotic Combinations on Pulse and Chase Labeling  ...............  56 
Effects of Antibiotic Combinations on 70S Ribosome Synthesis   ................  70 
Effects of Antibiotic Combinations on Western Blot Analysis  ......................  80 
Effects of Antibiotic Combinations on Agilent Bioanalysis of Total Cellular 
RNA  ...........................................................................................................        87  
Effects of Antibiotic Combinations on Northern Blot Hybridization  ..............  91 
Effects of Antibiotic Combinations on Mutation Frequency Assays .............  97 
 4. DISCUSSION  .................................................................................................  98 
	   9	  
IC50 Determination  .......................................................................................  99 
Cellular Growth Rates  .................................................................................  99 
Cellular Viability  ...........................................................................................  99 
DNA Synthesis Rates  ..................................................................................  99 
RNA Synthesis Rates ...................................................................................  99 
Protein Synthesis Rates  ..............................................................................  99 
Pulse and Chase Labeling  ..........................................................................  101 
70S Ribosome Synthesis   ...........................................................................  101 
Western Blot Analysis  .................................................................................  100 
Agilent Bioanalysis of Total Cellular RNA ....................................................  103 
Northern Blot Hybridization  .........................................................................  103 
Mutation Frequency Assays .........................................................................  104 
Summary ......................................................................................................  105  
REFERENCES ........................................................................................................  107 
VITA   .......................................................................................................................      117 
 
 
 
 
 
 
 
 
	   10	  
LIST OF TABLES 
Table Page 
1. Antibiotics used in combination studies with their targets and their mechanism 
of action.         ..........................................................................................................   23 
2. The percent of control rate for viable cell counts and cellular doubling time at       
IC50 for single or multiple antibiotic growths. ...........................................................  46 
3. The percent of control rate for DNA synthesis, RNA synthesis, and Protein 
synthesis.       ..........................................................................................................  55 
4. Pulse/chase rates are based on the percent of the control amounts of 
ribosomal subunits at 60 minutes in the presence of different antibiotic 
combinations. ..........................................................................................................  69 
5. 70S ribosome synthesis for all samples represented as a percent of total 
gradient CPM for the top fractions, the subunits and the 70S ribosome. ................  80 
6. Western blot analysis for total cellular protein from Staphylococcus aureus 
under different antibiotic condition and probed for RNAP β, DNA gyrase A, DNA 
gyrase B, and GAPDH and normalized as a percentage of the control. .................  86 
7. Agilent chip data.   ...............................................................................................  90 
8. Northern blot hybridization analysis taken as a percentage of the control total 
area signal for RNA from Staphylococcus aureus grown in the presence of 
different antibiotic combinations at IC50 and probed for 16S and 23S RNA. ...........  96 
9. Mutation frequencies for different antibiotic combinations.  Percent of single 
antibiotic control shown in parentheses.   ...............................................................  97 
 
	   11	  
LIST OF FIGURES 
Figure Page 
1. Overview of Antibiotic Use  .................................................................................  20 
2. Structure of Azithromycin (An Azalide)  ..............................................................  25 
3. Structure of Rifampicin (A Rifamycin family member) .........................................  26 
4. Structure of Ciprofloxacin (A Fluoroquinolone) ...................................................  27 
5. A model showing how a decrease in 50S ribosomal subunit amounts caused 
by azithromycin inhibition can lead to reduced levels of RNA polymerase and 
DNA gyrase (topoisomerase II), making them more sensitive to rifampicin or 
ciprofloxacin.  ..........................................................................................................  30 
6a. Growth rates of Staphylococcus aureus at different azithromycin 
concentrations.   ......................................................................................................  40 
6b. Growth rates of Staphylococcus aureus at different rifampicin  
concentrations.   ......................................................................................................  41 
6c. Growth rates of Staphylococcus aureus at different ciprofloxacin  
concentrations.   ......................................................................................................  42   42 
7a. Growth rates of cells grown in the presence of azithromycin, rifampicin, or 
ciprofloxacin at their IC50.   ......................................................................................  43 
7b. Growth rates of cells grown in the combinations of azithromycin + rifampicin, 
rifampicin + ciprofloxacin, azithromycin + ciprofloxacin or azithromycin + 
rifampicin + ciprofloxacin at each of the IC50 for each antibiotic .............................  44 
8. Staphylococcus aureus cell viability in the presence of antibiotic combinations.  45 
	   12	  
9a. Incorporation of 3H thymidine (1 µCi/mL) in Staphylococcus aureus cells after 
two cellular doublings in the presence of single antibiotics at the IC50. ...................  47 
9b. Incorporation of 3H thymidine (1 µCi/mL) in Staphylococcus aureus cells after 
two cellular doublings in the presence of multiple antibiotics at the IC50. ................  48 
10a. Incorporation of 3H uridine (1 µCi/mL) in Staphylococcus aureus cells after 
two cellular doublings in the presence of single antibiotics at the IC50. ...................  50 
10b. Incorporation of 3H uridine (1 µCi/mL) in Staphylococcus aureus cells after 
two cellular doublings in the presence of multiple antibiotics at the IC50. ................  51 
11a. Incorporation of 3H alanine (1 µCi/mL) in Staphylococcus aureus cells after 
two cellular doublings in the presence of single antibiotics at the IC50. ...................  53 
11b. Incorporation of 3H alanine (1 µCi/mL) in Staphylococcus aureus cells after 
two cellular doublings in the presence of multiple antibiotics at the IC50. ................  54 
12a. Sucrose gradient profiles showing distribution of 3H-uridine in lysates from 
control cells, collected after 10 minutes and 60 minutes of labeling.  .....................  57 
12b. Sucrose gradient profiles showing distribution of 3H-uridine in lysates from 
azithromycin treated cells, collected after 10 minutes and 60 minutes of labeling. .  58 
12c. Sucrose gradient profiles showing distribution of 3H-uridine in lysates from 
rifampicin treated cells, collected after 10 minutes and 60 minutes of labeling.  ....  59 
12d. Sucrose gradient profiles showing distribution of 3H-uridine in lysates from 
ciprofloxacin treated cells, collected after 10 minutes and 60 minutes of labeling.   60 
12e. Sucrose gradient profiles showing distribution of 3H-uridine in lysates from 
azithromycin + rifampicin treated cells, collected after 10 minutes and 60 minutes 
of labeling.  ...........................................................................................................       61 
	   13	  
12f. Sucrose gradient profiles showing distribution of 3H-uridine in lysates from 
rifampicin + ciprofloxacin treated cells, collected after 10 minutes and 60 minutes 
of labeling.  ...........................................................................................................        62 
12g. Sucrose gradient profiles showing distribution of 3H-uridine in lysates from 
azithromycin + ciprofloxacin treated cells, collected after 10 minutes and 60 
minutes of labeling. .................................................................................................  63 
12h. Sucrose gradient profiles showing distribution of 3H-uridine in lysates from 
azithromycin + rifampicin +ciprofloxacin treated cells, collected after 10 minutes 
and 60 minutes of labeling. .....................................................................................  64  
12i. Pulse/chase analysis of 30S subunit synthesis. ...............................................  65 
12j. Pulse/chase analysis of 30S subunit synthesis. ...............................................  66 
12k.Pulse/chase analysis of 50S subunit synthesis.   .............................................  67 
12l. Pulse/chase analysis of 50S subunit synthesis.   .............................................  68 
13a. 70S sucrose gradient profiles for 3H-uridine in lysates from control and 
azithromycin treated cells.   .....................................................................................  72 
13b. 70S sucrose gradient profiles for 3H-uridine in lysates from control and 
rifampicin treated cells. ...........................................................................................  73 
13c. 70S sucrose gradient profiles for 3H-uridine in lysates from control and 
ciprofloxacin treated cells. .......................................................................................  74 
13d. 70S sucrose gradient profiles for 3H-uridine in lysates from control and 
azithromycin + rifampicin treated cells. ...................................................................  75 
13e. 70S sucrose gradient profiles for 3H-uridine in lysates from control and 
rifampicin + ciprofloxacin treated cells. ...................................................................  76 
	   14	  
13f. 70S sucrose gradient profiles for 3H-uridine in lysates from control and 
azithromycin + ciprofloxacin treated cells. ...............................................................  77 
13g. 70S Sucrose gradient profiles for 3H-uridine in lysates from control and 
azithromycin + rifampicin + ciprofloxacin treated cells. ...........................................  78 
13h. Analysis of 70S subunit synthesis for all samples as a percent of the total 
gradient 3H CPM in the presence of different antibiotic combinations.    ................  79 
14a. Western blot analysis for total cellular protein from Staphylococcus aureus 
under different antibiotic condition and probed for RNAP β, DNA gyrase A, DNA 
gyrase B, and GAPDH. ...........................................................................................  81 
14b. Western blot analysis for total RNAP β protein from Staphylococcus aureus 
under different antibiotic condition shown as a percentage of the control. .............  82 
14c. Western blot analysis for DNA gyrase A protein from Staphylococcus aureus 
under different antibiotic condition shown as a percentage of the control. .............  83 
14d. Western blot analysis for DNA gyrase B protein from Staphylococcus 
aureus under different antibiotic condition shown as a percentage of the control. .  84 
14e. Western blot analysis for GAPDH protein from Staphylococcus aureus 
under different antibiotic condition shown as a percentage of the control.   ...........  85 
15a. Agilent chip analysis of Staphylococcus aureus RNA grown in the presence 
of different antibiotic combinations at IC50.   ............................................................  88 
15b. Agilent chip analysis of Staphylococcus aureus RNA grown in the presence 
of different antibiotic combinations at IC50 shown as a percentage of total area for 
small RNA, 16S RNA and 23S RNA. ......................................................................  89 
	   15	  
16a. Northern blot hybridization of RNA from Staphylococcus aureus grown in 
the presence of different antibiotic combinations at IC50 and probed for  
16S RNA.    ...........................................................................................................        92 
16b. Northern blot hybridization analysis of RNA from Staphylococcus aureus 
grown in the presence of different antibiotic combinations at IC50 and probed for 
16S RNA shown as a percentage of the control for total area signal.   ...................  93 
16c. Northern blot hybridization of RNA from Staphylococcus aureus grown in the 
presence of different antibiotic combinations at IC50 and probed for 23S RNA.   ...  94 
16d. Northern blot hybridization analysis of RNA from Staphylococcus aureus 
grown in the presence of different antibiotic combinations at IC50 and probed for 
23S RNA shown as a percentage of the control for total area signal.   ...................  95 
 
 
 
 
 
 
 
 
 
 
 
 
	   16	  
LIST OF ABBREVIATIONS 
 
AZI: Azithromycin 
BSA: Bovine serum albumin 
CFU: Colony forming units 
CIP: Ciprofloxacin 
CPM: Counts per minute 
EDTA: Ethylenediaminetetraacetic acid 
ETSH: β-mercaptoethanol 
GAPDH: Glyceraldehyde 3-phosphate dehydrogenase 
IC50: half maximal inhibitory concentration 
MIC: minimum inhibitory concentration 
PAGE: Polyacrylamide gel electrophoresis 
PMSF: phenylmethanesulfonyl fluoride 
RNAP: RNA polymerase 
RIF: Rifampicin 
SAS: Staphylococcus aureus S buffer 
SDS: sodium dodecyl sulfate 
SSC: saline-sodium citrate 
TAE: Tris-acetate-EDTA 
TCA: trichloroethanoic acid 
TE: Tris EDTA 
TRIS-HCL: trisaminomethane hydrochloride 
	   17	  
TSB: Tryptic soy broth 
TX-100: Triton X 100 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   18	  
CHAPTER 1 
INTRODUCTION 
 
Antibiotic Overview 
  
  As a growing threat to public health, antibiotic resistance is a prevalent 
and increasing concern in the medical field (1). Excessive use of antibiotics when 
treating humans, animals, or agriculture is thought to be a major contributor to 
this problem.  Figure 1 shows a detailed diagram of antibiotic use in humans, 
animals, and the environment and shows how this overuse can lead to these 
organisms becoming resistant to the antimicrobial chemicals used to combat 
them (2-5). 
 
  Bacteremia initiated by staphylococcal infections, particularly 
Staphylococcus aureus infections, can be a serious cause for alarm.  Urgent and 
thorough elimination of the infection is critical to the well being of patients with 
infection (6).  Antibiotic resistance in species such as Staphylococcus aureus 
was thought to be hospital acquired, but many studies have now shown that 
community-acquired infections are becoming more prevalent (7, 8).  Just a few 
years after the first antibiotics were used to fight the spread of pathogens, 
resistance to penicillin began occurring.  In the 1990s methicillin resistant 
Staphylococcus aureus was found to no longer be nosocomial but was now 
community-acquired and spread more often (8). 
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  In order to fight this serious problem, novel antibiotics, new antibiotic 
targets, and new methods to combat resistance are necessary (9, 10).  Areas of 
research on new targets showing no current resistance are highly sought, and 
researchers are desperately attempting to discover these new targets every day.   
 
  Antibiotic resistance occurs through several different mechanisms, such 
as modification of targets, acquisition of resistant genes, spontaneous mutations 
and up-regulation of genes encoding cellular efflux pumps (8).  Knowledge of 
these and other mechanisms can create a better understanding of current ways 
to treat antibiotic resistance and allow for increased response and success when 
fighting this global problem.  
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Overview of Antibiotic Use 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Overview of antibiotic use 
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Antibiotic Targets 
  
  The bacterial ribosome consists of a small 30S and a large 50S subunit 
(11).  The 16S ribosomal RNA (rRNA) and 21 proteins make up the 30S subunit, 
while 23S rRNA and 34 proteins make up the 50S subunit (12).  In order to 
create the bacterial ribosome, both subunits must be present and are essential to 
translation that uses specific centers for each subunit.  The decoding center is 
located in the 30S subunit, essential to the A binding site, with the peptidyl-
transferase center, essential to the P binding site, located in the 50S subunit 
(13).  A substantial amount of research has shown that antibiotics targeting the 
30S and 50S subunits inhibit both bacterial protein synthesis and subunit 
assembly, indicating that inhibition of ribosomal subunit assembly may be a 
synergistic process with translational inhibition (11, 14-17).  
 
  Translational inhibition is the target for many antibiotics, such as the 
macrolides (11, 12, 14).  During translation, mRNA transfers a genetic code to 
the ribosome, and tRNA carries the amino acids to the ribosome.  Both the 
mRNA and tRNA must move through the ribosome in order for the process to 
continue.  The progression of this is from the A site to the P site and lastly 
through the E site of the ribosome.  Thus, the ribosome serves as a platform for 
the tRNA to read the mRNA and create a nascent polypeptide chain.  This 
elongation cycle must include the decoding of the mRNA at the small ribosomal 
subunit by tRNA (within the A site), the formation of a peptide bond (the P site), 
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and the release of the tRNA molecule at the peptidyl-transferase center of the 
large ribosomal subunit (18).  After decoding the mRNA at the A site, the tRNA 
carrying the nascent polypeptide chain moves to the P site for peptide bond 
formation.  The tRNA that is ready to exit the ribosome is then moved to the E 
site after transferring the amino acid to the nascent peptide chain, leaving it 
uncharged (12).  In order to repeat this cycle once the mRNA has been read, the 
ribosomal subunits of the 70S ribosome must be recycled (6, 14, 18-21).  This is 
the final step in the protein synthesis cycle.  Antibiotics can act by targeting the 
decoding and PTC centers in order to inhibit protein synthesis (12).  In addition to 
this, another target of many antibiotics is the assembly and formation of the 
bacterial ribosome (11, 22).  When this assembly of ribosomal subunits is 
inhibited, ribonucleases degrade ribosomal assembly intermediates (11) (see 
Table 1). 
 
  Other targets for antibiotics include DNA synthesis and the transcription 
process (23).  One group of antibiotics that inhibit DNA synthesis is the 
fluoroquinolones (24).  They act by targeting DNA gyrase (topoisomerase II 
activity), which is involved in DNA negative supercoiling and are thus involved 
with the replication of the chromosome.  This is necessary and essential for the 
survival of bacteria not only because of replication but also because of repair, 
RNA transcription, and the recombination of DNA.  DNA gyrase causes the 
relaxation of DNA and when inhibited by an antibiotic such as ciprofloxacin, DNA 
synthesis is inhibited causing bacteriostatic and eventually bactericidal effects to 
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occur (23).  Other antibiotics inhibit the transcription of DNA to RNA as their 
target (25).  Rifamycins have the ability to bind to and inhibit bacterial DNA-
dependent RNA polymerase.  These antibiotics have a bacteriostatic activity due 
to binding to the β subunit of the RNAP and preventing the holoenzyme from 
initiating RNA synthesis (23) (see Table 1). 
 
Table 1.  Antibiotics used in combination studies with their targets and their 
mechanisms of action 
Antibiotic  Target Inhibitory Effect 
Azithromycin 50S ribosomal subunit 
exit tunnel (23S RNA) 
Inhibitor of translation 
and ribosomal subunit 
assembly 
Ciprofloxacin DNA gyrase (subunit A) Inhibitor of replication 
(Activity of 
Topoisomerase II)  
Rifampicin RNA Polymerase (β 
subunit) 
Inhibitor of 
transcription initiation 
 
 
Azithromycin 
    
  Azithromycin, used primarily for pathogens causing middle ear infections, 
strep throat, pneumonia, and bronchitis, is one of the most prescribed antibiotics 
worldwide (23, 26, 27).  An azalide derivative of erythromycin, it has an altered, 
more flexible 15 membered ring structure that allows it to occupy more space in 
the exit tunnel of the 50S ribosome when compared to other macrolides (28-32). 
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By binding to the upper portion of the peptide exit tunnel below the PTC of the 
50S ribosome, this antibiotic blocks any newly made peptide chains from 
elongating (6).  The use of azithromycin instead of other macrolides allows for a 
shorter peptide chain to form because of the larger size of azithromycin and is, 
thus, a more effective antibiotic. This occurs with only a single molecule of 
azithromycin being able to bind to a single ribosome at one time (33).  Macrolides 
including azithromycin have also been shown to bind to an intermediate of the 
50S subunit, the 32S precursor particle.  During growth in the presence of 
azithromycin, there is an accumulation of the 32S precursor .  This is indicative of 
stalling of the assembly of the 50S ribosomal subunit (34-36).  Macrolide 
selectivity has also been determined based on the adenine at position 2058 of 
23S rRNA—conserved in bacteria, but in eukaryotes there is a guanine residue 
(14, 37, 38) (see Fig.2 Table 1). 
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Figure 2. Structure of Azithromycin (An Azalide). A 15 membered macrolactone 
ring with an azide in the ring.  The desosamine sugar is essential for binding to 
23S RNA.  
 
Rifampicin 
 
  Rifampicin is a member of the rifamycin family and acts by binding to the 
beta subunit of the bacterial RNA polymerase, inhibiting transcription (25, 39).  It 
is primarily used as part of treatment regimens for tuberculosis and meningitis. 
The heavy use of rifampicin after it’s clinical introduction in the early 1960s 
resulted in resistance after just a few decades, due to monotherapy, especially in 
	   26	  
common pathogens such as Staphylococcus aureus (23).  Two mutational 
changes are responsible for high resistance levels in Staphylococcus aureus: 
His526->Asn, and Ser574->Leu.  Because of this high resistance, combinations 
of rifampicin with another antibacterial agents are commonly used to delay 
emergence of resistant strains (23, 40-43) (see Fig. 3 Table 1). 
 
 
Figure 3. Structure of Rifampicin (A Rifamycin family member)  
 
Ciprofloxacin 
 
  Ciprofloxacin is a fluoroquinolone and acts by targeting the topoisomerase 
II activity of DNA gyrase and inhibits DNA replication (44). It is used to treat 
infections by many bacterial pathogens causing respiratory, urinary tract, 
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gastrointestinal, and abdominal infections.  Since its introduction in 1987 it has 
been a largely successful antibiotic, but chromosome mutations are associated 
with resistance, especially in Staphylococcus aureus (23, 45).  While some 
research has indicated an irreversibility to this resistance by fluoroquinolones in 
an antibiotic free environment, it is now also used in combination with other 
antibiotics such as rifampicin (46-49) (see Fig. 4 Table 1). 
 
 
 
Figure 4. Structure of Ciprofloxacin (A Fluoroquinolone)  
 
Combination Therapy 
 
  Although several different antibiotics have had success in treating 
staphylococcal infections, resistance has continued to plague any advances 
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made in the field (6).  Methicillin-resistant Staphylococcus aureus (MRSA) and 
vancomycin-resistant Staphylococcus aureus are examples of the development 
of resistance to certain antibiotics that can lead to potentially life-threatening 
infections.  The emergence of strains now frequently resistant to rifampicin and 
ciprofloxacin has lead to antibiotics being used in combination as a way to most 
effectively fight resistance (41, 50). Combination therapy for these types of 
infections has been used to prevent the emergence of resistance when a single 
agent has been rendered ineffective (2, 9, 51, 52). These dual-antibiotic 
therapies have shown to be useful in reducing the time of bacteremia and have 
become vital for treatment against multidrug resistant strains of bacteria, 
including MRSA and multidrug resistant tuberculosis(53) . 
   
  Along with helping to reduce the occurrence of resistant cells when 
antibiotics are used in combinations, this method of antibiotic use also allows for 
lower concentrations of each antibiotic being used because of the efficiency of 
using 2 or more antibiotics.  This more effective way of treating infections caused 
by harmful pathogens also reduces other health concerns that have been 
associated with high antibiotic use (6, 54, 55).  
 
  Using two or more antibiotics targeting 2 or more essential cellular targets 
is a very effective way of eliminating the pathogen while also reducing or 
preventing the rate of recurrence (6).  Using rifampicin, (a transcription inhibitor), 
ciprofloxacin (a replication inhibitor), and azithromycin (a translation inhibitor) in 
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combinations could have devastating effects for harmful pathogens by inhibiting 
the flow of genetic information in each of the essential process for protein 
synthesis in a biological system.  Based on the prior research showing the 
inhibition of assembly of ribosomes by azithromycin, this use of antibiotics in 
combinations with azithromycin could also allow for synergistic effects on the 
assembly of the bacterial ribosome as well   A model for this process is shown in 
Figure 5.    
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Model 
 
  
 
Figure 5.  A model showing how a decrease in 50S ribosomal subunit amounts 
caused by azithromycin inhibition can lead to reduced levels of RNA polymerase 
and DNA gyrase (topoisomerase II), making them more sensitive to rifampicin or 
ciprofloxacin.  
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Research Hypothesis 
 
  Current research has shown that 2 important targets for several classes of 
antibiotics are the inhibition of bacterial ribosomal subunit assembly and 
translation (11, 56, 57). Azithromycin is an azalide derivative of erythromycin that 
inhibits translation by targeting the bacterial ribosome (28, 58).    Two other 
antibiotics also have inhibitory effects on staphylococcal infections.  
Ciprofloxacin, a fluoroquinolone, functions to inhibit DNA gyrase, inhibiting 
replication and rifampicin, a rifamycin, has an inhibitory effect on RNA 
polymerase, inhibiting transcription (23). (Table 1)  Figure 5 shows my proposed 
model of the different targets for these 3 antibiotics.  Their effects on target 
inhibition are shown to result from effects on ribosomal subunit synthesis.  I 
hypothesize that the use of different antibiotics known for their inhibitory effects 
on Staphylococcus aureus in combinations with azithromycin, known for its 
inhibitory effects on the bacterial ribosome, can create potential synergistic, 
additive, or antagonistic effects.  This can either improve or hinder the inhibition 
of protein synthesis via increased inhibition of subunit assembly leading to 
reduced levels of RNA polymerase and DNA gyrase as well (see Figure 5). 
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Specific Research Aims 
 
Aim 1. Effects of single and multiple antibiotics on cell growth rates, cell viability, 
and synthesis rates for DNA, RNA, and protein in Staphylococcus aureus. 
 
Aim 2. Effects of antibiotic combinations on synthesis rates of ribosomal subunits 
of Staphylococcus aureus. 
 
Aim 3. Effects of antibiotic combinations on amounts of gyrase, RNAP, and 70S 
ribosomes in Staphylococcus aureus. 
 
Aim 4. Effects of antibiotic combinations on RNA amounts and degradation in 
Staphylococcus aureus. 
 
Aim 5. Effects of antibiotic combinations on mutation frequency in 
Staphylococcus aureus. 
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CHAPTER 2 
MATERIALS AND METHODS 
 
Analysis of Cellular Growth and Viability 
  Staphylococcus aureus (ATCC 29213) was grown at 37°C in tryptic soy 
broth (TSB).  Growth rates were measured over time as an increase in cell 
density using a Klett-Summerson colorimeter in the presence or absence of 
antibiotics.  At a Klett reading of 20, azithromycin, rifampicin, or ciprofloxacin 
were added in a single antibiotic treatment or in combinations of 2 or 3 antibiotics 
at each antibiotic’s measured IC50.  At a Klett reading of 80, after 2 cellular 
doublings, cellular viability was determined by TSB agar plate colony counting 
following serial dilutions.  
 
DNA Synthesis Assays 
  Staphylococcus aureus was grown as described in the presence or 
absence of the antibiotic combinations.  After two cellular doublings, 1 µCi/mL of 
3H thymidine was added.  Following the addition of the radioisotope, three 0.2 mL 
samples were removed at 5-minute intervals and precipitated in 10% TCA with 
100 µg of BSA.  The samples were then vacuum collected and washed with 10% 
TCA on Whatman GF/A glass fiber filters.  The filters were placed into vials 
containing 3 mL Scintisafe gel.  Radioactivity was measured by liquid scintillation 
counting.  
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RNA Synthesis Assays 
  Staphylococcus aureus was grown as described in the presence or 
absence of the antibiotic combinations.  After 2 cellular doublings, 1 µCi/mL of 3H 
uridine was added.  Following the addition of the radioisotope, three 0.2 mL 
samples were removed at 5-minute intervals and precipitated in 10% TCA with 
100 µg of BSA.  The samples were then vacuum collected and washed with 10% 
TCA on Whatman GF/A glass fiber filters.  The filters were placed into vials 
containing 3 mL Scintisafe gel.  Radioactivity was measured by liquid scintillation 
counting. 
 
Protein Synthesis Assays 
  Staphylococcus aureus was grown as described in the presence or 
absence of the antibiotic combinations.  After 2 cellular doublings, 1 µCi/mL of 3H 
alanine was added.  Following the addition of the radioisotope, three 0.2 mL 
samples were isolated at 5-minute intervals and precipitated in 10% TCA with 
100 µg of BSA.  The samples were then vacuum collected and washed with 10% 
TCA on Whatman GF/A glass fiber filters.  The filters were placed into vials 
containing 3 mL Scintisafe gel.  Radioactivity was measured by liquid scintillation 
counting. 
 
Uridine Pulse and Chase Labeling 
  Twelve mL cultures of Staphylococcus aureus were grown to a Klett of 20 
and the previously mentioned antibiotic combinations were added.  After one 
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cellular doubling, the cells were pulse labeled with 3H uridine (1 µCi/mL) for 90 
seconds and then chased with uridine at a concentration of 25 µg/mL.  At 5 time 
intervals, 2 mL samples were removed, collected by centrifugation (5,000 RPM, 
15 minutes), and stored at -70°C before analysis by sucrose gradient 
centrifugation.  
 
70S Ribosome Synthesis Assay 
  Staphylococcus aureus was grown as described in the presence or 
absence of the antibiotic combinations.  After 15 minutes of growth with the 
antibiotics, 3H uridine (1 µCi/mL) and 2 µg/mL uridine were added.  After 2 
cellular doublings, 50 µg/mL uridine was added and the cells were grown for an 
additional 15 minutes.  Cells were then collected by centrifugation (5,000 RPM, 
15 minutes) and stored at -70°C before analysis by sucrose gradient 
centrifugation.  
 
Preparation of cellular lysates 
  Cell lysates were prepared by a lysostaphin-freeze thaw method. SAS 
buffer (80 µL ) (10mM Tris-HCL pH 8.0, 0.2 mM Mg acetate, 50 mM NH4Cl, 0.2 
mM mercaptoethanol), 25 µL lysostaphin (1 mg/mL), 25 µL lysozyme (1 mg/mL), 
5 µL phenylmethylsulfonyl fluoride (PMSF), and 1 µL RNasin were added to each 
frozen sample and incubated at 37°C for 15 minutes.  The lysates were then 
frozen at -70°C for 15 minutes and then thawed to room temperature.  DNAse I 
(2 µL ) and 3 µL Triton X-100 (TX-100) were then added and cell debris was 
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spun down at 6,000 RPM for 15 minutes.  Lysates were centrifugated through 5-
20% sucrose gradients in SAS buffer in a SW41 rotor at 187813 x g for 4 hours 
for subunits.  Following centrifugation, fractions were collected by pumping 
through an ISCO Model UA-5 absorbance monitor set at 254nm.  There were 31 
fractions collected into vials and mixed with 3 mL Scintisafe gel and radioactivity 
was measured by liquid scintillation counting.  
Note: R buffer (S buffer + 10mM Mg acetate) was used for 70S lysis and 
centrifugation was at 3.5 hours. 
 
Western Blot Analysis 
  Staphylococcus aureus was grown as above in the presence or absence 
of the previously mentioned antibiotic combinations.  Following the lysis 
procedure described, 1 volume of TCA was added and samples were put on ice 
for 15 minutes.  Samples were then spun at 14,000 RPM for 5 minutes.  The 
supernatant was removed and 200 µL acetone was added.  Samples were spun 
again, the supernatant was removed, and the protein was allowed to resuspend 
in sterile H2O.  1X NuPAGE LDS sample buffer was added to 60 µg of total 
protein for each sample and an SDS PAGE gel was run according to the 
manufacturer’s instructions for total protein (Invitrogen). Proteins were 
transferred to PVDF membranes (Santa Cruz, USA) and immunoblotting was 
performed with primary antibodies directed against RNAP β, DNA gyrase A and 
B, and GAPDH (Abcam) followed by HRP-conjugated secondary antibodies 
(Santa Cruz). The complexes were revealed using SuperSignal West Pico 
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Chemiluminescent Substrate (Thermo Scientific, Pierce).  Quantification was 
performed with a Fugi phosphoimager.  
 
Agilent Bioanalysis of Total Cellular RNA 
  Staphylococcus aureus was grown as described in the presence or 
absence of the antibiotic combinations.  After 2 cellular doublings in the presence 
of the antibiotic combinations, the cells were collected by centrifugation and RNA 
was extracted from the cell pellet using a phenol/chloroform extraction 
procedure. After lysates were spun down as described, the lysates were then 
added to 250 µL TE buffer and 500 µL phenol, vortexed and spun down. The 
supernatant was then added to another 500 µL phenol and the steps were 
repeated. One 0.5 volume of chloroform IAA (24:1) was then added to the 
supernatant and spun down.  The supernatant was then added to 2 volumes of 
absolute ethanol and was held at -70°C for 30 minutes.  The RNA was then spun 
down and washed with 70% ethanol, dried, and 25 µL sterile H2O was added to 
the RNA.  Concentration was measured by A260 reading from 1 µL.  Total RNA 
was examined using an Agilent Bioanalyzer 2100 and the RNA 6000 chip.  The 
sample preparation, loading procedure, and run were carried out according to the 
manufacturer’s instructions for total RNA analysis.  For each sample, 0.5 to 1.0 
µg of RNA was examined.   
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Northern Blot Hybridization 
  Staphylococcus aureus was grown as described in the presence or 
absence of the antibiotic combinations.  After 2 cellular doublings in the presence 
of the antibiotic combinations, the cells were collected by centrifugation and total 
RNA was extracted from the cell pellet using the  phenol/chloroform extraction 
procedure described.  
  Biotinylated 16S and 23S specific probes were constructed by PCR.  The 
16S (241 bp) and 23S (101bp) DNA probes were amplified from plasmid 
pKK3535 DNA using the polymerase chain reaction with primers from Life 
Technologies.  The Staphylococcus aureus 23S primers used were (23MET-F) 
GTAACGATTTGGGCACTGT and (23MET-R) AAGCTCCACGGGGTCT (nt nos. 
2002-2013).  The universal 16S primers used were (16U-F) 
GGAGGAAGGTGGGGATGACG and (16U-R) ATGGTGTGACGGGCGGTGTG 
(nt nos. 1173—1414).  PCR products were purified by extraction with phenol and 
chloroform and precipitated with 2 volumes of ethanol.  The DNA was 
resuspended in 30 µL of sterile water.  The purified DNA probes were labeled 
with biotin using the Label-IT biotin labeling kit (Mirus).     
  Total RNA (20 µg) was denatured by heating at 55°C for 10 minutes and 
separated on a 5% TAE PAGE gel.  RNA was transferred from the gel onto 
Nytran nylon membranes using a Turbo Blot apparatus (S&S).  The membranes 
were prehybridized in 15 mL of 1X prehybridization solution (5X SSC, 0.1 % 
sarkosyl, 0.02% SDS, 200 µg/mL BSA, H2O) at 42°C for 30 minutes.  The 
membranes were hybridized over night at 42°C with 6 mL hybridization buffer, 1X 
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background quencher, and 2µL of the denatured 16S or 23S specific biotinylated 
probe. 
 
  After hybridization, the membranes were washed and the probe was 
detected by the North2South chemiluminescent hybridization kit (Pierce 
Chemical co.) with streptavidin-conjugated horseradish peroxidase.  Quantitative 
analysis of the rRNA fragmentation was determined by a Fugi phosphoimager.  
 
Mutation Frequency Assays 
  Staphylococcus aureus (ATCC 29213) was grown at 37°C in tryptic soy 
broth (TSB). At a Klett reading of 20, azithromycin, rifampicin, or ciprofloxacin 
were added singly at increasing concentrations to measure the MIC for each. 
 
  Antibiotics at the MIC concentration were added to TSB agar plates and 
Staphylococcus aureus was grown as described without antibiotics.  At a Klett of 
160 (4 cellular doublings with antibiotics) cells were centrifugated and 
concentrated 10 fold before plating 0.1 mL on antibiotic plates with antibiotics at 
MIC.  CFUs were counted after incubating at 37°C over night.  
  
Statistical Analysis 
   A Student’s t-test has determined statistical differences in assays.  An 
asterisk indicates a statistical significance with P < 0.05. 
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CHAPTER 3 
RESULTS 
IC50 Determination 
  After growing Staphylococcus aureus (ATCC 29213) with azithromycin, 
rifampicin, or ciprofloxacin at different concentrations, the IC50 for each antibiotic 
was determined. Fig 6a shows the IC50 for azithromycin (0.2 µg/mL), Fig 6b 
shows the IC50 for rifampicin (0.003 at µg/mL), and Fig 6c shows the IC50 for 
ciprofloxacin (1.0 µg/mL) (see Figures 6a-c). 
           
Figure 6a. Growth rates of Staphylococcus aureus at different azithromycin 
concentrations.  Dashed line shows an IC50 of 0.2 µg/mL. (N=3, bars=standard 
deviation) 
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Figure 6b. Growth rates of Staphylococcus aureus at different rifampicin 
concentrations.  Dashed line shows an IC50 of 0.003 µg/mL. (N=3, bars=standard 
deviation) 
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Figure 6c. Growth rates of Staphylococcus aureus at different ciprofloxacin 
concentrations.  Dashed line shows an IC50 of 1.0 µg/mL. (N=3, bars=standard 
deviation) 
 
 
 
 
 
 
 
 
Growth Rates at Multiple Ciprofloxacin Concentrations 
0.0 0.5 1.0 1.5 2.0
0
10
20
30
40
50
60
70
80
90
100
Ciprofloxacin (µg/mL) 
Pe
rc
en
t o
f C
on
tr
ol
 G
ro
w
th
 R
at
e
	   43	  
Effects of Antibiotic Combinations on Cellular Growth Rates 
 
  Cells were grown at the IC50 for each antibiotic for several hours to 
measure growth rates. Doubling times were measured for growth in the presence 
of single antibiotics or in combinations.  Control cells had a doubling time of 32.5 
minutes.  Growth with single antibiotics showed a doubling time of approximately 
twice that of the control as expected (see Fig. 7a Table 2). 
 
 
Figure 7a. Growth rates of cells grown in the presence of azithromycin, 
rifampicin, or ciprofloxacin at their IC50.   
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Growth in the presence of antibiotic combinations had doubling times from 51 
minutes (Rif + Cip) to 140.9 minutes (Azi + Rif + Cip) (see Fig. 7b Table 2). 
 
Figure 7b. Growth rates of cells grown in the combinations of azithromycin + 
rifampicin, rifampicin + ciprofloxacin, azithromycin + ciprofloxacin or azithromycin 
+ rifampicin + ciprofloxacin at each of the IC50 for each antibiotic.  
 
Effects of Antibiotic Combinations on Cellular Viability 
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decrease in cells grown in the presence of azithromycin and rifampicin (24%) 
when compared to those grown with azithromycin or rifampicin alone (92% and 
66%).  A further decrease was observed when ciprofloxacin was added along 
with azithromycin and rifampicin (7.5%).  Ciprofloxacin in combination with only 
azithromycin, however, resulted in a slight increase when compared to cells 
grown with only ciprofloxacin (see Fig. 8 Table 2). 
 
 
Figure 8. Staphylococcus aureus cell viability in the presence of antibiotic 
combinations. (N=3 bars=standard deviation) Antibiotics were used at IC50 
determined by cell growth.  CFU were measured by dilution and plating on TSB 
pates after 2 cellular doublings in each case. 100% = 2.5 x 108 cells/mL 
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Table 2.  The percent of control rate for viable cell counts and cellular doubling 
time at IC50 for single or multiple antibiotic growths. 
Antibiotic Cell Growth (tD min)  CFU (x106/mL) 
Control (No Drug) 32.5  253.7 ± 26.5 
 
Azithromycin 67.1  
(48%) 
233.7 ± 93.3 
(92.1%) 
Rifampicin 70.9 
(46%) 
167.0 ± 50.6 
(65.8%) 
Ciprofloxacin 67.1  
(48%) 
4.67± 2.9 * 
(1.8%) 
Azi + Rif 122.2 
(27%) 
60.6 ± 46.3 * 
(23.9%) 
Rif + Cip 51.0  
(64%) 
12.7 ± 1.5 * 
(5.0%) 
Azi + Cip 92.3  
(35%) 
1.33 ± 1.5 * 
(0.5%) 
Azi + Rif + Cip 140.9  
(23%) 
19.0 ± 3.0 *  
(7.5%) 
Percent of control in parentheses. (*) Statistically significant with a P value < 
0.05. 
 
Effects of Antibiotic Combinations on DNA Synthesis Rates 
 
DNA synthesis rates showed a sharp decrease in cells grown with 
ciprofloxacin alone (6.5% of the control).  Cells grown with azithromycin, 
rifampicin or a combination of both resulted in small changes in DNA synthesis 
rates when compared to the control.  However, when in combination with 
ciprofloxacin for a triple antibiotic treatment, DNA synthesis rates increased when 
compared to cells grown in the presence of ciprofloxacin alone (6.1-54.5% of the 
control) (see Fig. 9a,b Table 3). 
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Figure 9a. Incorporation of 3H thymidine (1 µCi/mL) in Staphylococcus aureus 
cells after 2 cellular doublings in the presence of single antibiotics at the IC50. 
Samples taken at 5, 10, and 15 minutes. (N=3, bars=standard deviation) 
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Figure 9b. Incorporation of 3H thymidine (1 µCi/mL) in Staphylococcus aureus 
cells after 2 cellular doublings in the presence of multiple antibiotics at the IC50. 
Samples taken at 5, 10, and 15 minutes. (N=3, bars=standard deviation) 
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Effects of Antibiotic Combinations on RNA Synthesis Rates 
 
  RNA synthesis rates showed decreases in all 3 single antibiotic treated 
samples, with ciprofloxacin showing the largest decrease in synthesis rates (23% 
of control).  The double antibiotic treated cells showed little change in the 
azithromycin and rifampicin treated cells and a slight increase in synthesis rates 
for cells grown in the presence of azithromycin and ciprofloxacin.  The triple 
antibiotic treated cells showed the sharpest decrease for combination treated 
cells, but with a comparable rate to that of the cells grown with only ciprofloxacin 
(28%) (see Fig. 10a,b Table 3). 
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Figure 10a.Incorporation of 3H uridine (1 µCi/mL) in Staphylococcus aureus cells 
after 2 cellular doublings in the presence of single antibiotics at the IC50. Samples 
taken at 5, 10, and 15 minutes. (N=3, bars=standard deviation) 
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Figure 10b. Incorporation of 3H uridine (1 µCi/mL) in Staphylococcus aureus 
cells after 2 cellular doublings in the presence of multiple antibiotics at the IC50. 
Samples taken at 5, 10, and 15 minutes. (N=3, bars=standard deviation) 
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Effects of Antibiotic Combinations on Protein Synthesis Rates 
 
Protein synthesis measurements showed decreases in rates for all 3 
samples grown in the presence of a single antibiotic with the cells grown with 
azithromycin showing the sharpest decrease (41% of control).  Rifampicin in 
combination with azithromycin resulted in a further decrease in synthesis with the 
triple antibiotic treated cells showing a comparable rate (20% of control).  
Ciprofloxacin in combination with azithromycin resulted in a further reduction in 
synthesis (37%) when compared to cells grown in the presence of only 
ciprofloxacin, but was not as much of a decrease when compared to the 
azithromycin and rifampicin treated samples or the triple antibiotic samples (19%) 
(see Fig. 11a,b Table 3). 
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Figure 11a. Incorporation of 3H alanine (1 µCi/mL) in Staphylococcus aureus 
cells after 2 cellular doublings in the presence of single antibiotics at the IC50. 
Samples taken at 5, 10, and 15 minutes. (N=3, bars=standard deviation) 
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Figure 11b. Incorporation of 3H alanine (1 µCi/mL) in Staphylococcus aureus 
cells after 2 cellular doublings in the presence of multiple antibiotics at the IC50. 
Samples taken at 5, 10, and 15 minutes. (N=3, bars=standard deviation) 
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Table 3.  The percent of control rate for DNA synthesis, RNA synthesis, and 
Protein synthesis.   
Antibiotic DNA Synthesis 
 
RNA synthesis 
 
Protein synthesis 
 
Control (No Drug) 211.6 ± 28.8 5275.0 ± 420.4 197.2 ± 21.7 
Azithromycin 178.9 ± 30.6 
(85%) 
4323.2 ± 873.7 
(82%) 
81.5 ± 4.2 * 
(41.3%) 
Rifampicin 194.6 ± 41.9 
(92%) 
3322.7 ± 889.17 * 
(63%) 
176.5 ± 57.2  
(89.5%) 
Ciprofloxacin 13.7 ± 5.8 * 
(6.5%) 
1223.6 ± 135.6 * 
(23.2%) 
100.2 ± 41.0 * 
(50.8%) 
Azi + Rif 115.5 ± 21.7 * 
(54.5%) 
3200.4 ± 784.1 * 
 (60.7%) 
39.0 ± 13.7 * 
 (19.8%) 
Rif + Cip 13.0 ± 3.9 * 
(6.1%)  
131.2 ± 5.5 * 
(2.5%)  
24.8 ± 1.9* 
(12.6%)  
Azi + Cip 16.2 ± 2.6* 
(7.7%) 
1967.9 ± 336.6* 
(37.3%) 
72.9 ± 9.6* 
(37.0%) 
Azi + Rif + Cip 39.6 ± 10.4 *  
(18.7%) 
1493.6 ± 708.2*  
(28.3%) 
38.2 ± 6.7*  
(19.4%) 
Values are 3H-CPM/min from figures 9.1-11.2 (*) Statistically significant with a P 
value < 0.05. 
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Effects of Antibiotic Combinations on Pulse and Chase Labeling 
 
In order to determine the rates of ribosomal subunit synthesis in the 
presence or absence of antibiotics, pulse-chase labeling of ribosomal RNA was 
carried out.   
 
Pulse-chase studies for control cells revealed a 2:1 ratio of 50S to 30S 
ribosomal subunit formation (28% and 16% of total gradient counts respectively).  
Cells grown in the presence of azithromycin revealed a 10% and 15% decrease 
in 30S and 50S subunits, respectively.  When grown in combination with 
rifampicin or ciprofloxacin, subunit synthesis rates for the 30S subunit both 
decreased by 13-17% when compared to the cells grown in the presence of 
azithromycin alone.   
 
The 50S subunit synthesis rate for cells grown in the presence of 
azithromycin and ciprofloxacin resulted in a decrease from the rates for 
azithromycin alone (56% of control).  The largest decreased was observed in 
cells treated with azithromycin along with rifampicin or ciprofloxacin, where a 20-
30% decrease for 50S subunit synthesis was observed when compared to cells 
grown in the presence of azithromycin alone (see Fig.12a-l Table 4).  
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Figure 12a. Sucrose gradient profiles showing distribution of 3H-uridine in lysates 
from control cells, collected after 10 minutes and 60 minutes of labeling. 
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Figure 12b. Sucrose gradient profiles showing distribution of 3H-uridine in lysates 
from azithromycin treated cells, collected after 10 minutes and 60 minutes of 
labeling. 
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Figure 12c. Sucrose gradient profiles showing distribution of 3H-uridine in lysates 
from rifampicin treated cells, collected after 10 minutes and 60 minutes of 
labeling. 
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Figure 12d. Sucrose gradient profiles showing distribution of 3H-uridine in lysates 
from ciprofloxacin treated cells, collected after 10 minutes and 60 minutes of 
labeling. 
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Figure 12e. Sucrose gradient profiles showing distribution of 3H-uridine in lysates 
from azithromycin + rifampicin treated cells, collected after 10 minutes and 60 
minutes of labeling. 
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Figure 12f. Sucrose gradient profiles showing distribution of 3H-uridine in lysates 
from rifampicin + ciprofloxacin treated cells, collected after 10 minutes and 60 
minutes of labeling. 
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Figure 12g. Sucrose gradient profiles showing distribution of 3H-uridine in lysates 
from azithromycin + ciprofloxacin treated cells, collected after 10 minutes and 60 
minutes of labeling. 
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Figure 12h. Sucrose gradient profiles showing distribution of 3H-uridine in lysates 
from azithromycin + rifampicin + ciprofloxacin treated cells, collected after 10 
minutes and 60 minutes of labeling. 
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Figure 12i. Pulse/chase analysis of 30S subunit synthesis. Rates are shown as a 
percent of the total gradient 3H CPM for samples treated with single antibiotics. 
3H radioactivity was summed for the 30S peak region (fractions 11-15).  
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Figure 12j. Pulse/chase analysis of 30S subunit synthesis. Rates are shown as a 
percent of the total gradient 3H CPM for samples treated in antibiotic 
combinations. 3H radioactivity was summed for the 30S peak region (fractions 11-
15). 
 
 
 30S Subunit Synthesis Rates +/- Antibiotics in 
Staphylococcus aureus 
0 10 20 30 40 50 60
0
5
10
15
20
25
30
30S %T Con
30S %T Azi/Rif
30S %T Rif/Cip
30S %T Azi/Cip
30S %T Azi/Rif/Cip
Minutes
Pe
rc
en
t T
ot
al
 G
ra
di
en
t 3
H
 C
PM
	   67	  
 
Figure 12k. Pulse/chase analysis of 50S subunit synthesis.  Rates are shown as 
a percent of the total gradient 3H CPM for samples treated with single antibiotics.  
3H radioactivity was summed for the 50S peak region (fractions 19-24). 
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Figure 12l. Pulse/chase analysis of 50S subunit synthesis.  Rates are shown as 
a percent of the total gradient 3H CPM for samples treated in antibiotic 
combinations.  3H radioactivity was summed for the 50S peak region (fractions 
19-24). 
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Table 4. Pulse/chase rates are based on the percent of the control amounts of 
ribosomal subunits at 60 minutes in the presence of different antibiotic 
combinations. 
Antibiotic 30S Subunit 
 
50S Subunit 
 
Control (No Drug) 16.5 ± 0.8 28.4 ± 1.8 
Azithromycin 14.9 ± 0.8 
(90.3%) 
24.3 ± 1.3 
(85.6%) 
Rifampicin 7.6 ± 0.2 * 
(46.1%) 
12.5 ± 1.1 * 
(44.0%) 
Ciprofloxacin 9.4 ± 0.3 * 
(57.0%) 
20.5 ± 0.6 * 
(72.2%) 
Azi + Rif 12.7 ± 3.2 
(77.0%) 
18.7 ± 1.8 * 
(65.8%) 
Rif + Cip 11.1 ± 1.2 * 
(67.3%) 
22.3 ± 3.2 
(78.5%) 
Azi + Cip 11.9 ± 7.1 
(72.1%) 
15.9 ± 6.6 
(56.0%) 
Azi + Rif + Cip 14.5 ± 2.2 
(87.9%) 
22.9 ± 1.8 
(80.6%) 
 (*) Statistically significant with a P value < 0.05. 
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Effects of Antibiotic Combinations on 70S Ribosome Synthesis 
 
  In order to determine the effects of antibiotics on target amounts, 70S 
ribosome synthesis, RNA polymerase, and DNA gyrase levels were measured 
under each antibiotic combination through 2 assays. 
 
  In order to determine the effects of the antibiotics on 70S ribosome 
synthesis, 70S formation was measured using 3H-uridine to measure the 
amounts of ribosomes.  The 70S ribosome, the 30S and 50S subunits and any 
RNA in the top gradient regions for each sample were quantified by summing 3H 
CPM after sucrose gradient centrifugation. 
 
  Control cells were found to have 70S ribosomes + polysomes as 32.1% of 
the total gradient CPM.  Samples that resulted in significant differences when 
compared to these control cells were cells grown with rifampicin (0.85% of total 
CPM), cells grown with azithromycin + rifampicin or ciprofloxacin (0.55% and 
0.45% respectively) cells grown with all 3 antibiotics (1.05% of the total gradient 
CPM) (see Fig 13a-h Table 5). 
 
  Along with measuring 70S ribosome synthesis, the total gradient CPM of 
ribosomal subunits and the top gradient regions for each sample were 
determined.  The same samples showing significant differences in 70S ribosome 
synthesis also showed significant differences in the amounts of both subunits 
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when compared to the control (13.1% total CPM for control, 1.7-6% for 
significantly different samples).  The top gradient regions for these same samples 
showed significant increases in the amount of degraded RNA at the top of each 
gradient. (49.9% total gradient CPM for control, 92-98% for significantly different 
samples) (see Fig 13a-h Table 5). 
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Figure 13a. 70S sucrose gradient profiles for 3H-uridine in lysates from control 
and azithromycin treated cells. Control 70S ribosome with polysomes, subunits, 
and 3H RNA in the top gradient region is shown. 
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Figure 13b. 70S sucrose gradient profiles for 3H-uridine in lysates from control 
and rifampicin treated cells. Control 70S ribosome with polysomes, subunits, and 
3H RNA in the top gradient region is shown. 
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Figure 13c. 70S sucrose gradient profiles for 3H-uridine in lysates from control 
and ciprofloxacin treated cells. Control 70S ribosome with polysomes, subunits, 
and 3H RNA in the top gradient region is shown. 
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Figure 13d. 70S sucrose gradient profiles for 3H-uridine in lysates from control 
and azithromycin + rifampicin treated cells. Control 70S ribosome with 
polysomes, subunits, and 3H RNA in the top gradient region is shown. 
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Figure 13e. 70S sucrose gradient profiles for 3H-uridine in lysates from control 
and rifampicin + ciprofloxacin treated cells. Control 70S ribosome with 
polysomes, subunits, and 3H RNA in the top gradient region is shown. 
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Figure 13f. 70S sucrose gradient profiles for 3H-uridine in lysates from control 
and azithromycin + ciprofloxacin treated cells. Control 70S ribosome with 
polysomes, subunits, and 3H RNA in the top gradient region is shown. 
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Figure 13g. 70S Sucrose gradient profiles for 3H-uridine in lysates from control 
and azithromycin + rifampicin + ciprofloxacin treated cells. Control 70S ribosome 
with polysomes, subunits, and 3H RNA in the top gradient region is shown. 
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Figure 13h. Analysis of 70S subunit synthesis for all samples as a percent of the 
total gradient 3H CPM in the presence of different antibiotic combinations. 
Percentage of total gradient 3H in top fractions (1-10), 30S and 50S (11-20) 
subunits, and 70S subunits + polysomes (21-31) is shown. 
 
 
 
 
 
 
70S Ribosome Synthesis in Staphylococcus aureus
1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3
0
10
20
30
40
50
60
70
80
90
100
Control
Azithromycin
Rifampicin
Ciprofloxacin
Azi/Rif
Rif/Cip
Azi/Cip
Azi/Rif/Cip
1. Top Fractions
2. Subunits
3. 70S Ribosome
Antibiotic Combinations
Pe
rc
en
t T
ot
al
 G
ra
di
en
t 3
H
 C
PM
	   80	  
Table 5. 70S ribosome synthesis for all samples represented as a percent of 
total gradient CPM for the top fractions, the subunits and the 70S ribosome.  
Antibiotic 70S Ribosome Subunits Top Fractions 
Control (No Drug) 32.1 ± 4.6 13.1 ± 1.5 49.9 ± 7.0 
Azithromycin 22.6 ± 4.9 19.4 ± 0.8 51.8 ± 6.9 
Rifampicin 0.850 ± 0.1 * 6.00 ± 0.1 * 92.7 ± 0.7 * 
Ciprofloxacin 24.3 ± 4.7  14.9 ± 2.0 51.0 ± 5.7 
Azi + Rif 0.550 ± 0.1 * 2.60 ± 0.4 * 96.7 ± 0.3 * 
Rif + Cip 0.450 ± 0.1 * 3.90 ± 0.2 * 95.4 ± 0.2 * 
Azi + Cip 20.1 ± 2.3  20.1 ± 2.0 56.2 ± 0 
Azi + Rif + Cip 1.05 ± 1.0 * 1.70 ± 0.4 * 98.2 ± 0.5 * 
 (n=3, bars=standard deviation) (*) Statistically significant with a P value < 0.05. 
 
Effects of Antibiotic Combinations on Western Blot Analysis 
 
  To measure the amounts of total target protein in Staphylococcus aureus 
grown in each of the antibiotic conditions described, Western blot analysis was 
carried out.  Antibodies specific to each of the cellular targets for each antibiotic 
were used (see Fig. 14a). Samples probed for GAPDH as a control showed no 
significant differences among any samples from cells grown in the presence or 
absence of antibiotics (see Fig. 14a,e Table 6). Samples probed for RNAP β 
showed no significant differences in cells in the presence or absence of drug 
(see Fig 14a,b Table 6). Samples probed for DNA gyrase A showed statistically 
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significant differences in samples treated with azithromycin + rifampicin, and in 
the presence of all 3 antibiotics. A large increase was observed in samples 
treated with ciprofloxacin alone (see Fig. 14a,c Table 6). Samples probed for 
DNA gyrase B showed statistically significant differences in samples grown in the 
presence of ciprofloxacin alone (see Fig 14a,d Table 6). 
 
Western Blot Analysis 
 
 
 
 
 
 
Figure 14a. Western blot analysis for total cellular protein from Staphylococcus 
aureus under different antibiotic condition and probed for RNAP β, DNA gyrase 
A, DNA gyrase B, and GAPDH.  
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Figure 14b. Western blot analysis for total RNAP β protein from Staphylococcus 
aureus under different antibiotic condition shown as a percentage of the control. 
(n=2, bars=standard deviation)  
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Figure 14c. Western blot analysis for DNA gyrase A protein from 
Staphylococcus aureus under different antibiotic condition shown as a 
percentage of the control. (n=2, bars=standard deviation) 
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Figure 14d. Western blot analysis for DNA gyrase B protein from 
Staphylococcus aureus under different antibiotic condition shown as a 
percentage of the control. (n=2, bars=standard deviation) 
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Figure 14e. Western blot analysis for GAPDH protein from Staphylococcus 
aureus under different antibiotic condition shown as a percentage of the control. 
(n=2, bars=standard deviation) 
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Table 6. Western blot analysis for total cellular protein from Staphylococcus 
aureus under different antibiotic condition and probed for RNAP β, DNA gyrase 
A, DNA gyrase B, and GAPDH and normalized as a percentage of the control. 
Values are mean areas of scans of two blots. (*) Statistically significant with a P 
value < 0.05. 
 
 
 
Antibiotic GAPDH 
 
RNAP β 
 
DNA Gyrase A DNA Gyrase B 
Control (No Drug) 51390 ± 1240 15112 ± 3588 528 ± 36 224 ± 22  
Azithromycin 53143 ± 2860 
(103%) 
14728 ± 4903 
(97%) 
448 ± 18  
(85%) 
92 ± 20 
(41%) 
Rifampicin 50229 ± 7751 
(98%) 
21557 ± 4609 
(142%) 
757 ± 108  
(143%) 
202 ± 43 
(90%) 
Ciprofloxacin 50130 ± 7383  
(98%) 
18797 ± 6360 
(124%) 
835 ± 100 
(158%) 
857 ± 7 * 
(383%) 
Azi + Rif 54852 ± 5751  
(107%) 
17774 ± 1630 
 (118%) 
19 ± 9 * 
(3.6%) 
72 ± 6 
(32%) 
Rif + Cip 53639 ± 5745 
(104%)  
17732 ± 1990  
(117%)  
238 ± 55 
(45%) 
214 ± 5 
(96%) 
Azi + Cip 55075 ± 4761 
(107%) 
15587 ± 839 
(103%) 
497 ± 66 
(94%) 
17 ± 8 
(8%) 
Azi + Rif + Cip 54659 ± 5255  
(106%) 
12044 ± 2178  
(80%) 
146 ± 39 * 
(28%) 
66 ± 34 
(29%) 
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Effects of Antibiotic Combinations on Agilent Bioanalysis of Total Cellular RNA 
 
To determine and analyze the amounts of ribosomal RNA in cells grown 
under the different antibiotic combinations, Agilent chip electrophoresis was 
performed.  The amounts of small degraded RNA, 16S RNA, and 23S RNA were 
quantitated.   
 
The largest amounts of degradation were found in samples grown with 
azithromycin (159% compared to control), rifampicin (160%), and azithromycin + 
rifampicin (189%) as indicated by the amount of small RNA fragments in each of 
those samples (see Fig.15a,b Table 7). 
 
In these samples a decrease in the amounts of 16S RNA was observed. 
The same samples also showed the largest decrease in the amount of 23S RNA 
when compared to the control and were found to be statistically significant (see 
Fig.15a,b Table 7). 
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Agilent Bioanalysis of Total Cellular RNA 
                   
 
         
 
Figure 15a. Agilent chip analysis of Staphylococcus aureus RNA grown in the 
presence of different antibiotic combinations at IC50.  Increases in small rRNA 
were observed in antibiotic treated samples. 
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Figure 15b. Agilent chip analysis of Staphylococcus aureus RNA grown in the 
presence of different antibiotic combinations at IC50 shown as a percentage of 
total area for small RNA, 16S RNA and 23S RNA.  
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Table 7.  Agilent chip data.   
Antibiotic Small RNA 16S RNA 23S RNA 
Control (No Drug) 24.7 ± 3 19.8 ± 0.2 40.2 ± 1.3 
Azithromycin 39.3 ± 0.1 * 
(159%) 
23.8 ± 1.3 
(120%) 
32.9 ± 0.7 * 
(82%) 
Rifampicin 39.6 ± 0.5 * 
(160%) 
23.8 ± 0.1 * 
(120%) 
32.3 ± 0.8 * 
(80%) 
Ciprofloxacin 38.2 ± 1.6  
(155%) 
18.9 ± 0.2  
(95%) 
39.5 ± 1.6  
(98%) 
Azi + Rif 46.7 ± 0.6 * 
(189%) 
21.5 ± 0.2 * 
(109%) 
26.2 ± 0.8 * 
(65%) 
Rif + Cip 31.4 ± 0.8  
(127%) 
28.6 ± 0.2 * 
(144%) 
40.1 ± 0.6  
(100%) 
Azi + Cip 38.4 ± 2.7  
(155%) 
27.6 ± 1.5 * 
(139%) 
34.0 ± 1.2 
(85%) 
Azi + Rif + Cip 36.9 ± 0.7 
(149%) 
26.6 ± 0.1 * 
(134%)  
36.6 ± 0.7  
(91%) 
Percentage of small RNA, 16S, and 23S RNA regions as a percent of the total 
area.  Values are areas of peaks from Agilent software.  (*) Statistically 
significant with a P value < 0.05. 
 
	   91	  
Effects of Antibiotic Combinations on Northern Blot Hybridization 
 
In order to observe the specific amounts of ribosomal RNA degradation in 
cells grown under the different antibiotic conditions, Northern blot hybridization 
was performed.  Using 16S and 23S DNA probes to detect the RNA, 2 different 
blots were carried out.  One with the total amount of RNA for each sample and 
one with the 16S and 23S bands removed in order for maximum detection of 
small RNA fragments.  
 
In the 16S blots large amounts of degradation were observed in the 
azithromycin (125% of control), azithromycin + rifampicin (130%), rifampicin + 
ciprofloxacin (122%), azithromycin + ciprofloxacin (145%), and azithromycin + 
rifampicin + ciprofloxacin (133%) treated cells when total RNA was probed, and 
for the azithromycin + rifampicin treated samples (207%) once the 16S band was 
removed and the RNA was probed again (see Fig 16a,b Table 8). 
 
In the 23S blots large amounts of degradation were observed in the 
azithromycin (258% of control), ciprofloxacin (339%), azithromycin + rifampicin 
(300%), and rifampicin + ciprofloxacin (209%) treated cells once the 23S band 
was removed (see Fig 16c,d Table 8). 
 
 
 
	   92	  
Northern Blot Hybridization for 16S RNA 
 
  
 
 
Figure 16a. Northern blot hybridization of RNA from Staphylococcus aureus 
grown in the presence of different antibiotic combinations at IC50 and probed for 
16S RNA.  Small rRNA fragments with 16S RNA removed are shown below for 
each. RNA fragment increases were seen in antibiotic treated samples. 
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Figure 16b. Northern blot hybridization analysis of RNA from Staphylococcus 
aureus grown in the presence of different antibiotic combinations at IC50 and 
probed for 16S RNA shown as a percentage of the control for total area signal.  
16S Degradation = area with 16S RNA removed.  
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Northern Blot Hybridization for 23S RNA 
 
 
 
 
 
Figure 16c. Northern blot hybridization of RNA from Staphylococcus aureus 
grown in the presence of different antibiotic combinations at IC50 and probed for 
23S RNA.  Small rRNA fragments with 23S RNA removed are shown below for 
each. RNA fragment increases were seen in antibiotic treated samples. 
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Figure 16d. Northern blot hybridization analysis of RNA from Staphylococcus 
aureus grown in the presence of different antibiotic combinations at IC50 and 
probed for 23S RNA shown as a percentage of the control for total area signal.  
23S Degradation = area with 23S RNA removed. 
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Table 8. Northern blot hybridization analysis taken as a percentage of the control 
total area signal for RNA from Staphylococcus aureus grown in the presence of 
different antibiotic combinations at IC50 and probed for 16S and 23S RNA. 
Antibiotic 16S Small RNA 
 
16S Total RNA 
 
23S Small RNA 
 
23S Total RNA 
 
Control (No Drug) 49.8 ± 23.6 100.8 ± 10.7 24.6 ± 4.7 57.5 ± 29.9  
Azithromycin 93.2 ± 21.8 
(187%) 
126.1 ± 8.3 * 
(125%) 
63.5 ± 8.0 * 
(258%) 
90.2 ± 31.5 
(157%) 
Rifampicin 63.1 ± 20.9 
(127%) 
97.9 ± 13.9 
(97.1%) 
37.7 ± 4.9  
(153%) 
95.7 ± 25.0 
(166%) 
Ciprofloxacin 105.3 ± 26.4  
(211%) 
119.5 ± 12.8 
(119%) 
83.4 ± 11.3 * 
(339%) 
108.2 ± 30.0 
(188%) 
Azi + Rif 103.1 ± 20.9 * 
(207%) 
130.6 ± 5.6 * 
 (130%) 
73.9 ± 8.0 * 
(300%) 
102.3 ± 21.9 
(178%) 
Rif + Cip 73 ± 24.6  
(147%)  
123.0 ± 4.3 *  
(122%)  
51.5 ± 6.0 * 
(209%) 
86.3 ± 25.4 
(150%) 
Azi + Cip 78.8 ± 30.3 
(158%) 
146.0 ± 8.3 * 
(145%) 
40.9 ± 3.9 
(166%) 
87.3 ± 19.6 
(152%) 
Azi + Rif + Cip 66.2 ± 29.1  
(133%) 
134.0 ± 12.8 * 
(133%) 
34.8± 3.5  
(141%) 
86.0 ± 15.1 
(150%) 
(*) Statistically significant with a P value < 0.05. 
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Effects of Antibiotic Combinations on Mutation Frequency Assays 
 
  Mutation frequency measurements were carried out to determine the 
levels of resistance occurring in cells grown in the presence of different antibiotic 
combinations.  Cells grown on plates containing 2 or 3 antibiotics showed 
decreases in the frequency of resistant cells.  When compared to cells grown in 
the presence of rifampicin or ciprofloxacin alone, cells grown under antibiotic 
combinations showed a significant decrease in resistant colonies. No triply 
resistant mutants were found. 
 
Table 9. Mutation frequencies for different antibiotic combinations.  Percent of 
single antibiotic control shown in parentheses.   
Antibiotic Azithromycin Rifampicin Ciprofloxacin Azi + Rif + Cip 
 
Azithromycin 1.8 x 10-8 
100% 
1.8 x 10-9 
10% 
3.7 x 10-10 
2% 
< 10-10 
Rifampicin 1.8 x 10-9 
3%* 
6.3 x 10-8 
100% 
1.9 x 10-9 
3%* 
< 10-10 
Ciprofloxacin 3.7 x 10-10 
0.5%* 
1.9 x 10-9 
2.5%* 
7.6 x 10-8 
100% 
< 10-10 
N=3 (*) Statistically significant with a P value < 0.05. 
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CHAPTER 4 
DISCUSSION 
 
  Current research from the lab of Champney has shown that 2 important 
targets for antibiotics are the inhibition of bacterial ribosomal subunit assembly 
and translation (11). Azithromycin is an azalide derivative of erythromycin that 
inhibits translation by targeting the bacterial ribosome.  Two other antibiotics also 
have inhibitory effects on staphylococcal infections.  Ciprofloxacin, a 
fluoroquinolone, functions to inhibit DNA gyrase, inhibiting replication and 
rifampicin, a rifamycin, has an inhibitory effect on RNA polymerase, inhibiting 
transcription (see Table 1).  Figure 5 shows my proposed model of the different 
targets for these three antibiotics. 
   
  The use of these different antibiotics known for their inhibitory effects on 
Staphylococcus aureus in combinations with azithromycin, known for its inhibitory 
effects on the bacterial ribosome, can create synergistic effects and improve the 
inhibition of protein synthesis via increased inhibition of subunit assembly leading 
to reduced levels of RNA polymerase and DNA gyrase as well. 
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IC50 Determination, Cellular Growth Rates and Cellular Viability 
 
  After IC50 values were determined for each antibiotic used, cells were 
grown in the described antibiotic combinations.  Growth rates for cells grown in 
the presence of a single antibiotic verified the concentrations used with doubling 
times roughly double that of the control and was consistent with previous data 	  
(59-61).  When grown in combination with 1 or 2 other antibiotics, slower growth 
resulted in doubling times increasing from 65 to 75% of the control.  Cells were 
then plated to determine viability and significant decreases were most prevalent 
in cells grown in the presence of multiple antibiotics.  In some cases viable cells 
were reduced to less than 10% of the control cells observed.  Compared to the 
doubly treated cells, treatment with all 3 antibiotics only resulted in a further 
reduction when compared to cells grown with azithromycin and rifampicin.  Cells 
treated with ciprofloxacin singly or doubly resulted in the fewest viable cells (see 
Fig 6a-c, 7a,b, 8, Table 2). 
 
DNA, RNA, and Protein Synthesis Rates 
 
  DNA, RNA, and protein synthesis rates were determined and showed 
significant decreases in synthesis rates, most noticeably in all assays for cells 
grown in the presence of multiple antibiotics.  
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  A significant decrease in DNA synthesis rate was also observed in cells 
grown in the presence of ciprofloxacin alone, and given its inhibition of 
replication, this was expected.  There were also significant decreases in RNA 
synthesis and protein synthesis for the same combinations, indicating a strong 
inhibition of most cellular activity due to the effects of ciprofloxacin alone (see 
Fig. 9a,b Table 3). 
 
  For RNA synthesis, growth in the presence of rifampicin alone was the 
most effective single antibiotic treated condition to have a significant inhibitory 
effect.  Growth in the presence of ciprofloxacin alone was the other single 
antibiotic condition resulting in a significant decrease in protein synthesis, due to 
low amounts of DNA replication, resulting in low amounts of transcription (see 
Fig. 10a,b Table 3). 
 
  Synergistic effects from the antibiotics in combination are evident by the 
strong decreases in the synthesis rates of RNA, DNA, and protein in cells grown 
in the presence of multiple antibiotics.  In most assays the triply treated cells 
showed large reductions in rates.  However, ciprofloxacin showed to have some 
antagonistic effects with used in combination with azithromycin.  In some cases 
rates were down to less than 5% of the control and for protein synthesis rates, 
cells grown with azithromycin and rifampicin or grown with all 3 antibiotics 
showed a greater than 50% reduction when compared to cells grown in the 
presence of azithromycin alone.  Results validate the idea presented in the 
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model (Fig. 5) of synergistic effects of combination antibiotic treatment (see Fig. 
11a,b Table 3). 
 
Pulse and Chase Labeling 
 
  Azithromycin contributed to a reduction of ribosomal subunits similar to 
previous work (11, 62).The rates of ribosomal subunit formation were determined 
and a significant reduction in the 50S subunit levels was observed in cells grown 
in the presence of azithromycin and rifampicin in combination.  Although other 
antibiotic combinations showed significant differences, this sample was of most 
importance as it shows an additive effect due to the inhibition of subunit 
synthesis and assembly with cells grown in the presence of not only an antibiotic 
already known for it’s inhibitory effects on the 50S subunit, but in this case 
rifampicin as well.  This is due to the inhibition of rRNA transcription in 
combination with translation inhibition (see Fig. 12a-l Table 4). 
 
70S Ribosome Synthesis and Western Blot Analysis 
 
  The 70S ribosome synthesis measurements showed large increases in 
small RNA species in lysates from cells grown in the presence of multiple 
antibiotics, indicating significant degradation of rRNA.  This was supported by the 
significant decreases in the amounts of 70S ribosomes in the samples treated 
with one or more antibiotics.  Cells treated with single antibiotics all resulted in an 
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increase in 30S and 50S ribosomal subunits and an increase in degradation, with 
a reduction of 70S ribosomes.  Cells grown in the presence of azithromycin in 
combination with one or two other antibiotics showed a further increase the 
amount of degradation and resulted in very little 70S ribosome or subunits, 
showing an additive effect for an antibiotic that already has a strong effect on the 
ribosome (see Fig. 13a-h, Table 5). 
 
  Looking at the 2 other targets, RNAP and DNA gyrase by Western 
immunoblotting, there were significant decreases in protein amounts when DNA 
gyrase amounts were measured in 2 cases (Azi+Rif and Azi+Rif+Cip for DNA 
gyrase A). There were, however, large increases in the amounts of DNA gyrase 
A when grown in the presence of ciprofloxacin alone.  Results were similar in 
DNA gyrase B but not as significant with an exception for cells grown with 
ciprofloxacin alone.  In this sample there was a significant increase in DNA 
gyrase B detected. As previous research suggests, because of the relatively low 
concentrations of antibiotics, an upregulation of transcription may have occurred 
given that ciprofloxacin treatments should target DNA gyrase, resulting in a 
reduction, not a large increase in protein produced (63). This was also the case 
when amounts of RNAP were measured.  Samples grown in the presence of 
rifampicin or ciprofloxacin showed an increase in amounts of RNAP.  Although 
this increase occurred, along with slight decreases in RNAP in samples grown in 
the presence of 2 or more antibiotics, results were not found to be significantly 
different from that of the control (see Fig. 14a-e Table 6). 
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Agilent Bioanalysis of Total Cellular RNA and Northern Blot Hybridization 
 
  Agilent analysis of rRNA supported previous results when measuring 
subunit synthesis.  Samples from cells grown in the presence of single antibiotics  
showed increases in degradation, with small rRNA fragments observed.  A 
further increase occurred in samples from cells grown in the presence of multiple 
antibiotics.  The combination of azithromycin and rifampicin resulted in the 
largest amount of degradation and was found to be significantly greater than any 
degradation occurring in cells grown without antibiotics. As a result of the 
increase of degradation occurring, smaller amounts of 23S rRNA were observed 
in antibiotic treated samples (see Fig. 15a,b Table 7). 
 
  Northern blot hybridization and detection of 16S RNA showed degradation 
for samples treated with azithromycin and an increase in degradation observed in 
samples treated with azithromycin in combination with other antibiotics that was 
shown to be statistically significant (see 16a,b Table 8). 
 
  Northern blot hybridization and detection of 23S RNA showed degradation 
for samples treated with azithromycin or ciprofloxacin and a large increase in 
degradation observed in samples treated with azithromycin in combination with 
rifampicin and in samples grown with ciprofloxacin and rifampicin that were 
shown to be statistically significant (see 16c,d Table 8). 
 
	   104	  
  Analysis of rRNA provided additional evidence for an increase of inhibition 
of subunit synthesis when cells are grown with azithromycin in combination with 
other antibiotics.  Samples determined to be significant different were also 
consistent with assays and measurements for subunit and 70S ribosome 
synthesis evaluated under the same antibiotic combinations.  
 
Mutation Frequency Assays 
 
  Mutation frequencies were determined by growing cells in the absence of 
antibiotics and plating onto TSB agar containing antibiotic combinations at their 
determined MICs with results consistent with previous data (25, 45, 48, 64-70).  
Very few colonies were observed in any sample with significant decreases in 
CFUs observed in cases of cells grown on plates containing azithromycin + 
rifampicin and azithromycin + ciprofloxacin.  No observable colonies were seen 
on plates containing all 3 antibiotics, providing strong evidence for a reduction in 
resistance when cells are grown in antibiotic combinations.  For plates containing 
rifampicin or ciprofloxacin in combination with azithromycin this supports 
combination use considering the high resistance rates for pathogens treated with 
only rifampicin or ciprofloxacin (see Table 9). 
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Summary 
 
  In summary, these data show support not only for the use of antibiotic 
combination therapy but have shown evidence for an increase in the inhibition of 
bacterial ribosome assembly in Staphylococcus aureus. Strong evidence of the 
reduction of 50S ribosomal subunit synthesis and 23S ribosomal RNA in cells 
grown in the presence of azithromycin, already known for its inhibitory effects on 
the 50S subunit synthesis, in combination with rifampicin or in combination with 
rifampicin and ciprofloxacin was observed (28). This also resulted in a reduction 
or elimination in the frequency of resistant cells when grown in the presence of 
these combinations.   
 
  Antibiotic resistance remains an increasing threat due to many different 
reasons.  Overuse of antibiotics has shown to contribute to this along with 
random genetic mutations contributing to this problem.  Evidence has also shown 
possible selectivity for antibiotics within the ribosomal exit tunnel (71).  The data 
provided here support the need for more insight into antibiotics that target 
ribosomal assembly as a means to inhibit protein synthesis and resistance 
involving the exit tunnel.  If assembly were thoroughly inhibited, there would be 
no ribosomes to develop resistance.  With recent warnings by the FDA for 
dangerous side effects of azithromycin use that could (in rare cases) result in 
abnormal heart rhythms, this work is further support for the use of antibiotics in 
combinations with azithromycin (72).  This would allow for a more efficient way of 
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eliminating pathogens while also allowing for reduced concentrations of 
antibiotics administered to patients.   
 
  These studies have shed light on the mechanism of action involved and 
synergistic effects occurring in combination antibiotic treatments and how 
ribosomal subunit assembly is affected. The insights gained through this 
research provide necessary information needed for the design of more potent 
antibiotic combinations.   This will create a better understanding and new 
methods for eliminating the spread of harmful pathogens such as 
Staphylococcus aureus and warrants further investigation of this mechanism of 
inhibition.  
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